Please assess the completion status of the following clinical trial:

Trial Title: Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically confirmed malignant mixed mesodermal (MMMT) confined to the pelvis (Stage IB, IC, IIA, IIB, IIIA).~* Patients who have undergone a total abdominal hysterectomy, vaginal hysterectomy or laparoscopic assisted vaginal hysterectomy and a bilateral salpino-oophorectomy (with minimal surgical staging, including omental biopsy and lymph node sampling) within 8 weeks of study entry.~* No known metastatic extrauterine metastases, no known gross residual disease or distant metastases.~* Women of any racial or ethnic group are eligible.~* Zubrod performance status of \</= 2.~* Adequate bone marrow, renal and hepatic function: Hgb \> 10 gm/dl, ANC \>1.5/mm3, Platelets \> 100,000/mcl, Creatinine \< 1.5 mg/%, Bilirubin \< 2.5 mg/dl, SGPT \< 2\* ULN, BUN \< 1.5\* ULN.~* No prior chemotherapy or radiation therapy for this diagnosis.~* Estimated life expectancy of 12 weeks or greater.~* Must sign an institutionally approved informed consent.~Exclusion Criteria:~* Previously treated malignant mixed mesodermal (MMMT) with either chemotherapy or radiotherapy (XRT)/~* Patients with gross residual disease, suspected extrapelvic or extrauterine disease or distant metastatic disease (Stage IIIB, IIIC or IV).~* History of other malignancy, with the exception of non-melanomatous skin cancer, unless in complete remission and off all therapy for that disease for a minimum of 5 years.~* Patients with a Zubrod performance status of 3 or greater.~* Patients with an active systemic infection.~* Patients with a serious intercurrent medical illness.~* Patients with a recent (within 6 months) history of cardiac dysrhythmia, congestive heart failure, unstable angina or myocardial infarction.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiation + Chemotherapy (Type: EXPERIMENTAL): Radiation with weekly Cisplatin 40 mg/m\^2 intravenously (IV) Followed by Carboplatin (AUC 5 IV)/Paclitaxel (135 mg/m\^2 IV) Chemotherapy every 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).